

**SERIES ADJUSTMENTS - 2005 - 195
ONN INFORMATION CIRCULAR # 1252
December 8, 2005**

ID Biomedical Corporation (IDBE/QQ) - Cash Settlement

On Wednesday, November 16, 2005, the shareholders of ID Biomedical Corporation (IDBE) approved the proposed Merger with GlaxoSmithKline Inc.(GSK). The merger was subsequently consummated on December 8, 2005. As a result, each existing IDBE Common Share will be converted into the right to receive the US Dollar equivalent of CDN \$35.00 net cash per share.

Pending Contract Adjustments

Pursuant to Options Clearing Corporation (OCC) by-laws, all outstanding ID Biomedical Corporation options will be adjusted as follows:

Adjustment Date: December 9,2005
New Deliverable/Contract: The US Dollar Equivalent of CDN \$3,500.00 (CDN 35.00 x 100)

***The foregoing is an unofficial summary of the terms of the Merger, prepared by the ISE for the convenience of its members. ISE accepts no responsibility for the accuracy or completeness of the summary. Members should refer to the proxy statement for the authoritative description of the merger terms and conditions.*

Questions regarding this release may be directed to Iris Rodriguez at (212) 897-0264.